How long do the effects of tucatinib last?

The duration of effect of Tucatinib varies depending on the patient's specific condition, treatment plan, individual differences and other factors.

In a pivotal clinical trial (HER2CLIMB), tucatinib, in combination with trastuzumab and capecitabine, significantly prolonged HER2Progression-free survival (PFS) and overall survival (OS) in patients with >positive metastatic breast cancer.

Specifically, the median PFS was 7.8 months in the tucatinib combination group and 5.6 months in the placebo combination group. This shows that tucatinib can prolong the disease control time of patients and slow down the progression of the disease.

In terms of overall survival, the median OS in the tucatinib combination group was 21.9 months, while the median OS in the placebo combination group was 17.4 months. This shows that tucatinib can prolong the survival time of patients and provide patients with more treatment opportunities.

It should be noted that the duration of effect of tucatinib varies depending on the patient's specific condition, treatment plan, individual differences and other factors. Therefore, a uniform duration of effect cannot be given.

For some patients, tucatinib may be able to control the disease and extend survival for a long time; while for other patients, the effect of tucatinib may be relatively short-lived.

The patient's specific condition, including tumor stage, grade, metastasis and other factors, will affect the duration of tucatinib's effect. Tucatinib is often given in combination with other drugs, and different combination regimens may affect the duration of its effects. Factors such as the patient's physical condition, immune system status, drug metabolism and excretion ability will also affect the duration of tucatinib's effect.

References:

https://pmc.ncbi.nlm.nih.gov/articles/PMC10722550/